



08-01-02

1645/16

Docket No. 2016-4010US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Jason D. Bannon, et al.

Group Art Unit: 1645

Serial No.: 09/335,581

Examiner: J.A. Hines

Filed: June 18, 1999

For: PEPTIDES USEFUL FOR REDUCING SYMPTOMS OF TOXIC SHOCK
SYNDROME AND SEPTIC SHOCK

EXPRESS MAIL CERTIFICATE

Express Mail Label No.: **EV 186618895 US**

Date of Deposit: **July 31, 2002**

RECEIVED

AUG 06 2002

TECH CENTER 1600/2900


I hereby certify that the following attached paper(s) and/or fee

1. Amendment Under 37 C.F.R. §1.111 (19 pages),
2. Petition for Two Month Extension of Time (2 pages),
3. Check in the amount of \$400.00, and
5. Return Receipt Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Commissioner for Patents, Washington, DC 20231

Jafet Cotto

(Typed or printed name of person mailing papers(s) and/or fee)


(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



RECEIVED

AUG 06 2002

TECH CENTER 1600/2900

Docket No. 2016-4010US2

Ande (24/1/02) Linda 8/13/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Jason D. Bannan et al.
Serial No. : 09/335,581 Group Art Unit: 1645
Filed : June 18, 1999 Examiner: J.A. HINES
For : PEPTIDES USEFUL FOR REDUCING SYMPTOMS OF TOXIC
SHOCK SYNDROME AND SEPTIC SHOCK

AMENDMENT UNDER 37 CFR §1.111

Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the Office Action mailed March 1, 2002. A response was due June 1, 2002 without an extension of time. Applicants have petitioned concurrently, however and paid the appropriate fee for a two month extension of time extending the date to respond to August 1, 2002.

Please amend the application as follows:

IN THE CLAIMS

50. (Twice amended) A non-toxic, purified peptide consisting essentially of an amino acid sequence selected from the group consisting of
CMYGGVTLHDGN (SEQUENCE ID NO: 32);
CMYGGVTLHNGN (SEQUENCE ID NO: 33);
CMYGGVTLHEGN (SEQUENCE ID NO: 34);
CMYGGVTLHQGN (SEQUENCE ID NO: 35);
CMYGGVTLHHGN (SEQUENCE ID NO: 36);
CMYGGVTEHDGN (SEQUENCE ID NO: 37);